As of 2024-09-09, the EV/EBITDA ratio of Acceleron Pharma Inc (XLRN) is -41.25. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Acceleron's latest enterprise value is 10,456.47 mil USD. Acceleron's TTM EBITDA according to its financial statements is -253.46 mil USD. Dividing these 2 quantities gives us the above Acceleron EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.9x - 21.7x | 17.0x |
| Forward P/E multiples | 19.9x - 24.6x | 22.6x |
| Fair Price | (78.13) - (85.52) | (77.54) |
| Upside | -143.7% - -147.8% | -143.4% |
| Date | EV/EBITDA |